If You Invested in Kintara Therapeutics, Inc. (KTRA)

Kintara Therapeutics, Inc. (formerly trading under the Nasdaq symbol KTRA) was a biopharmaceutical company focused on the development of new solid tumor cancer therapies. According to multiple company communications, Kintara was located in San Diego, California and concentrated on patients with unmet medical needs in oncology. The company later underwent a reverse merger and corporate transformation, with its stock expected to begin trading on a post-reverse-split basis on the Nasdaq Capital Market under the new name TuHURA Biosciences, Inc. and the new symbol HURA following the closing of a merger with TuHURA Biosciences, Inc.

Public disclosures describe Kintara as dedicated to developing therapeutics for clear unmet medical needs using reduced risk development programs. Its lead program was REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). Kintara reported that REM-001 Therapy is based on a proprietary, late-stage photodynamic therapy platform that had been studied as a localized cutaneous or visceral tumor treatment and in other potential indications. The REM-001 platform consists of three key components: a laser light source, a light delivery device, and the REM-001 drug product.

Company press releases state that REM-001 Therapy had previously been evaluated in four Phase 2/3 clinical trials in CMBC patients who had received chemotherapy and/or failed radiation therapy. In these disclosures, Kintara reported a clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and an existing safety database of approximately 1,100 patients across multiple indications. Kintara also highlighted an open-label REM-001 study in CMBC, supported in large part by a Small Business Innovation Research grant from the National Institutes of Health.

In addition to its clinical work, Kintara pursued a significant corporate transaction with TuHURA Biosciences, Inc., a Phase 3 registration-stage immuno-oncology company developing technologies to overcome resistance to cancer immunotherapy. Kintara entered into a definitive merger agreement with TuHURA, under which a wholly owned Kintara subsidiary, Kayak Mergeco, Inc., would merge with and into TuHURA, with TuHURA surviving as a direct, wholly owned subsidiary of Kintara. Company communications describe this as an all-stock transaction intended to combine oncology assets and technologies.

As part of this process, Kintara’s stockholders approved a reverse stock split of Kintara’s common stock in a range of 1-for-20 to 1-for-40, and the board of directors approved a final ratio of 1-for-35. Kintara disclosed that every thirty-five pre-split shares of its common stock would become one share of common stock, with the reverse split expected to reduce the number of outstanding shares while leaving the par value and authorized share count unchanged. The company stated that the reverse split would affect all stockholders uniformly, with fractional shares addressed by issuing additional fractions as needed to result in whole shares.

Press releases further noted that, following the closing of the merger with TuHURA, the combined company’s total outstanding common stock was expected to be approximately 42 million shares. In connection with the merger, Kintara also planned to issue Contingent Value Rights (CVRs) to its stockholders pursuant to a CVR Agreement. These CVRs were described as entitling holders to an aggregate number of shares of Kintara’s common stock (subject to adjustment for the reverse stock split) upon achievement of certain milestones related to the REM-001 study, with one CVR to be issued per share of Kintara common stock (or per underlying share for certain warrants) held immediately prior to the reverse stock split.

Subsequent SEC filings show that the legacy Kintara corporate shell became part of TuHURA Biosciences, Inc., with TuHURA identified as a Nevada corporation whose common stock trades on the Nasdaq Capital Market under the symbol HURA. These filings refer to TuHURA’s previously announced reverse merger with Kintara Therapeutics, Inc. that closed on October 18, 2024 and to TuHURA as the continuing registrant. Later filings also describe additional transactions by TuHURA, including an acquisition of Kineta, Inc. and related pro forma financial information, all under the HURA ticker.

For investors researching the historical KTRA symbol, it is important to recognize that Kintara’s business and listing transitioned through the merger into TuHURA Biosciences, Inc. The KTRA ticker represents the pre-merger Kintara entity focused on REM-001 photodynamic therapy and related oncology programs, while ongoing public company disclosures, financing activities, and subsequent acquisitions are made under TuHURA’s name and the HURA symbol.

Business focus and therapeutic platform

According to repeated company descriptions, Kintara concentrated on developing novel cancer therapies for solid tumors where patients have limited treatment options. Its late-stage photodynamic therapy platform, centered on REM-001 Therapy, was positioned as a localized treatment approach for cutaneous and potentially visceral tumors. The platform’s structure—laser light source, light delivery device, and drug product—was consistently highlighted in Kintara’s communications as the core of its therapeutic strategy.

In CMBC, Kintara emphasized that REM-001 Therapy had been studied in multiple Phase 2/3 trials in heavily pretreated patients and that the therapy had generated a substantial safety database across indications. The company also described CMBC as an area of unmet medical need and referenced an ongoing open-label REM-001 study in CMBC patients, with enrollment milestones tied to CVR payouts under the merger structure with TuHURA.

Corporate transformation into TuHURA Biosciences, Inc.

Through the reverse merger with TuHURA Biosciences, Inc., Kintara’s public listing was used to form a combined oncology company operating under the TuHURA name. Press releases indicated that, upon the anticipated closing of the merger, Kintara’s common stock would begin trading on a post-reverse-split basis on the Nasdaq Capital Market under the new name TuHURA Biosciences, Inc. and the symbol HURA. Subsequent SEC filings identify TuHURA Biosciences, Inc. as the registrant, with common stock registered under the HURA ticker.

Later regulatory filings by TuHURA reference the “reverse merger with Kintara Therapeutics, Inc. that closed on October 18, 2024,” confirming completion of the transaction and the transition from KTRA to HURA for ongoing public company reporting. These filings also show that TuHURA continued to execute additional corporate transactions, such as the acquisition of Kineta, Inc., under the TuHURA corporate structure.

Historical context for KTRA investors

For users examining the KTRA symbol on a historical basis, the key elements are:

• Kintara Therapeutics, Inc. was a San Diego, California–based biopharmaceutical company focused on novel cancer therapies for solid tumors and unmet medical needs.
• The company’s lead program was REM-001 Therapy, a photodynamic therapy platform for cutaneous metastatic breast cancer, composed of a laser light source, a light delivery device, and the REM-001 drug product.
• REM-001 Therapy had been studied in four Phase 2/3 clinical trials in CMBC patients who had received chemotherapy and/or failed radiation therapy, with company disclosures citing 80% complete responses in CMBC evaluable lesions and a safety database of approximately 1,100 patients across multiple indications.
• Kintara entered into a definitive merger agreement with TuHURA Biosciences, Inc., including a 1-for-35 reverse stock split and the issuance of CVRs tied to REM-001 study milestones.
• Following the closing of the merger, the public company name and ticker transitioned to TuHURA Biosciences, Inc. (HURA), with TuHURA serving as the continuing SEC registrant in subsequent filings.

FAQs about Kintara Therapeutics (KTRA)